Diagnostic Performance of Serum Biomarkers Fibroblast Growth Factor 21, Galectin-3 and Copeptin for Heart Failure with Preserved Ejection Fraction in a Sample of Patients with Type 2 Diabetes Mellitus
Open Access
- 30 August 2021
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 11 (9) , 1577
Abstract
More than half of the patients with heart failure have preserved ejection fraction (HFpEF), however evidence shows a mortality rate comparable to those with reduced ejection fraction. The aim of this study was to evaluate whether FGF21, galectin-3 and copeptin can be used as biomarkers to identify HFpEF in patients with confirmed type 2 diabetes mellitus (DM). Sixty-nine diabetic patients were enrolled and divided into two groups: patients with HFpEF (n = 40) and those without HFpEF (n = 29). The ability of the studied biomarkers to discriminate HFpEF cases from non-HFpEF subjects were evaluated by the area under the Receiver Operating Characteristics (ROC) curve and the 95% confidence interval (CI). Compared to patients without heart failure, those with HFpEF had significantly higher levels of FGF21 (mean 146.79 pg/mL vs. 298.98 pg/mL). The AUC value of FGF21 was 0.88, 95% CI: [0.80, 0.96], Se = 85% [70.2, 94.3], Sp = 79.3% [60.3, 92.0], at an optimal cut-off value of 217.40 pg/mL. There was no statistical significance associated with galectin-3 and copeptin between patient cohorts. In conclusion, galectin-3 and copeptin levels were not effective for detecting HFpEF, while FGF21 is a promising biomarker for diagnosing HFpEF in DM patients.Keywords
Funding Information
- Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca, Romania (1529)
This publication has 55 references indexed in Scilit:
- Prevalence, Clinical Phenotype, and Outcomes Associated With Normal B-Type Natriuretic Peptide Levels in Heart Failure With Preserved Ejection FractionThe American Journal of Cardiology, 2012
- Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated CopeptinCirculation: Heart Failure, 2011
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathNew England Journal of Medicine, 2011
- Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fractionAnnals of Medicine, 2010
- Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection FractionCirculation: Heart Failure, 2010
- Plasma Copeptin and the Risk of Diabetes MellitusCirculation, 2010
- HbA1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) studyDiabetologia, 2008
- Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failureEuropean Journal of Clinical Investigation, 2006
- Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of VasopressinClinical Chemistry, 2006
- FGF-21 as a novel metabolic regulatorJournal of Clinical Investigation, 2005